Systems biology analysis of protein-drug interactions

Proteomics - Clinical Applications

Volumn 6, Issue 1-2, 2012, Pages 102-116

  Colinge, Jacques ^a   Rix, Uwe ^a   Bennett, Keiryn L ^a   Superti Furga, Giulio ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Bioinformatics; Chemical proteomics; Drugs; Personalized medicine; Statistics

Indexed keywords

BAFETINIB; BOSUTINIB; DASATINIB; GEFITINIB; IMATINIB; PROTEOME;

ACCURACY; ALGORITHM; BINDING AFFINITY; BINDING COMPETITION; CHINESE MEDICINE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL COMPUTING; MOLECULAR DYNAMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; STRUCTURAL BIOINFORMATICS; STRUCTURAL PROTEOMICS; SYSTEMS BIOLOGY;

DRUG INTERACTIONS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS; PROTEINS; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 84858968611     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100077     Document Type: Review

References (105)

1. Domon, B., Aebersold, R., Mass spectrometry and protein analysis. Science 2006, 312, 212-217.
2. Bantscheff, M., Scholten, A., Heck, A. J., Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discov. Today 2009, 14, 1021-1029.
3. Rix, U., Superti-Furga, G., Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 2009, 5, 616-624.
4. Booth, B., Zemmel, R., Prospects for productivity. Nat. Rev. Drug Discov. 2004, 3, 451-456.
5. Csermely, P., Agoston, V., Pongor, S., The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 2005, 26, 178-182.
6. Araujo, R. P., Liotta, L. A., Petricoin, E. F., Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat. Rev. Drug Discov. 2007, 6, 871-880.
7. Keith, C. T., Borisy, A. A., Stockwell, B. R., Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 2005, 4, 71-78.
8. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L. et al., Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110, 4055-4063.
9. Hood, L., Heath, J. R., Phelps, M. E., Lin, B., Systems biology and new technologies enable predictive and preventative medicine. Science 2004, 306, 640-643.
10. Gavin, A.-C., Aloy, P., Grandi, P., Krause, R. et al., Proteome survey reveals modularity of the yeast cell machinery. Nature 2006, 440, 631-636.
11. Harding, M. W., Galat, A., Uehling, D. E., Schreiber, S. L., A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989, 341, 758-760.
12. Cuatrecasas, P., Wilchek, M., Anfinsen, C. B., Selective enzyme purification by affinity chromatography. Proc. Natl. Acad. Sci. USA 1968, 61, 636-643.
13. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S. et al., Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25, 1035-1044.
14. Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H. et al., In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 2011, 18, 699-710.
15. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B. et al., Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006, 127, 635-648.
16. Hantschel, O., Gstoettenbauer, A., Colinge, J., Kaupe, I. et al., The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol. Oncol. 2008, 2, 272-281.
17. Pan, C., Olsen, J. V., Daub, H., Mann, M., Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol. Cell. Proteomics 2009, 8, 2796-2808.
18. Li, J., Rix, U., Fang, B., Bai, Y. et al., A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 2010, 6, 291-299.
19. Winter, G. E., Rix, U., Lissat, A., Stukalov, A. et al., An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol. Cancer Ther. 2011.
20. Ramsden, N., Perrin, J., Ren, Z., Lee, B. D. et al., Chemoproteomics-based design of potent LRRK2- selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem. Biol. 2011.
21. Duncan, J. S., Gyenis, L., Lenehan, J., Bretner, M. et al., An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol. Cell. Proteomics 2008, 7, 1077-1088.
22. Mercer, L., Bowling, T., Perales, J., Freeman, J. et al., 2, 4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach. PLoS Negl. Trop. Dis. 2011, 5, e956.
23. Fadden, P., Huang, K. H., Veal, J. M., Steed, P. M. et al., Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem. Biol. 2010, 17, 686-694.
24. Kang, H. J., Yoon, T. S., Jeong, D. G., Kim, Y. et al., Identification of proteins binding to decursinol by chemical proteomics. J. Microbiol. Biotechnol. 2008, 18, 1427-1430.
25. Fleischer, T. C., Murphy, B. R., Flick, J. S., Terry-Lorenzo, R. T. et al., Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 2010, 17, 659-664.
26. Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O. et al., Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009, 23, 477-485.
27. Fernbach, N. V., Planyavsky, M., Muller, A., Breitwieser, F. P. et al., Acid elution and one-dimensional shotgun analysis on an Orbitrap mass spectrometer: an application to drug affinity chromatography. J. Proteome Res. 2009, 8, 4753-4765.
28. Lundgren, D. H., Hwang, S. I., Wu, L., Han, D. K., Role of spectral counting in quantitative proteomics. Expert Rev. Proteomics 2010, 7, 39-53.
29. Brehme, M., Hantschel, O., Colinge, J., Kaupe, I. et al., Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 2009, 106, 7414-7419.
30. Choi, H., Fermin, D., Nesvizhskii, A. I., Significance analysis of spectral count data in label-free shotgun proteomics. Mol. Cell. Proteomics 2008, 7, 2373-2385.
31. Rix, U., Remsing Rix, L. L., Terker, A. S., Fernbach, N. V. et al., A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia 2009, 24, 44-50.
32. Venkatesan, K., Rual, J. F., Vazquez, A., Stelzl, U. et al., An empirical framework for binary interactome mapping. Nat. Methods 2009, 6, 83-90.
33. Rhodes, D. R., Tomlins, S. A., Varambally, S., Mahavisno, V. et al., Probabilistic model of the human protein-protein interaction network. Nat. Biotechnol. 2005, 23, 951-959.
34. Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A. et al., Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 2011, 29, 255-265.
35. Liu, Y., Patricelli, M. P., Cravatt, B. F., Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. USA 1999, 96, 14694-14699.
36. Adam, G. C., Sorensen, E. J., Cravatt, B. F., Chemical strategies for functional proteomics. Mol. Cell. Proteomics 2002, 1, 781-790.
37. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
38. Thompson, A., Schafer, J., Kuhn, K., Kienle, S. et al., Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 2003, 75, 1895-1904.
39. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
40. Breitwieser, F. P., Muller, A., Dayon, L., Kocher, T. et al., General statistical modeling of data from protein relative expression isobaric tags. J. Proteome Res. 2011, 10, 2758-2766.
41. Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26, 1367-1372.
42. Sharma, K., Weber, C., Bairlein, M., Greff, Z. et al., Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 2009, 6, 741-744.
43. Kanehisa, M., Araki, M., Goto, S., Hattori, M. et al., KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008, 36, D480-D484.
44. Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J. et al., PID: the Pathway Interaction Database. Nucleic Acids Res. 2009, 37, D674-D679.
45. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D. et al., Gene ontology: tool for the unification of biology. Gene Ontol. Consortium Nat. Genet. 2000, 25, 25-29.
46. Huang da, W., Sherman, B. T., Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44-57.
47. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S. et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545-15550.
48. Colinge, J., Rix, U., Superti-Furga, G., in: Chen, L., Zhang, X., Shen, B., Wu, L., Wang, Y. (Eds.), 4th International Conference on Computational Systems Biology, World Publishing Company, Suzhou, China 2010, pp. 305-313.
49. Benjamini, Y., Hochberg, Y., Controlling the false discovery arte: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 1995, 57, 289-300.
50. Alexa, A., Rahnenfuhrer, J., Lengauer, T., Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006, 22, 1600-1607.
51. Tarca, A. L., Draghici, S., Khatri, P., Hassan, S. S. et al., A novel signaling pathway impact analysis. Bioinformatics 2009, 25, 75-82.
52. Glaab, E., Baudot, A., Krasnogor, N., Valencia, A., Extending pathways and processes using molecular interaction networks to analyse cancer genome data. Biomed. Chromatogr. Bioinformatics 2010, 11, 597.
53. Kerrien, S., Alam-Faruque, Y., Aranda, B., Bancarz, I. et al., IntAct - open source resource for molecular interaction data. Nucleic Acids Res. 2007, 35, D561-D565.
54. Cesareni, G., Chatr-aryamontri, A., Licata, L., Ceol, A., Searching the MINT database for protein interaction information. Curr. Protoc. Bioinformatics 2008. Chapter 8, Unit 8.5.
55. Breitkreutz, B. J., Stark, C., Reguly, T., Boucher, L. et al., The BioGRID Interaction Database: 2008 update. Nucleic Acids Res. 2008, 36, D637-D640.
56. Lynn, D. J., Winsor, G. L., Chan, C., Richard, N. et al., InnateDB: facilitating systems-level analyses of the mammalian innate immune response. Mol. Syst. Biol. 2008, 4, 218.
57. Prasad, T. S., Kandasamy, K., Pandey, A., Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol. Biol. 2009, 577, 67-79.
58. Burkard, T. R., Rix, U., Breitwieser, F. P., Superti-Furga, G., Colinge, J., A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib. PLoS Comput. Biol. 2010, 6, e1001001.
59. Jeong, H., Tombor, B., Albert, R., Oltvai, Z. N., Barabasi, A. L., The large-scale organization of metabolic networks. Nature 2000, 407, 651-654.
60. Kohler, S., Bauer, S., Horn, D., Robinson, P. N.,Walking the interactome for prioritization of candidate disease genes. Am. J. Hum. Genet. 2008, 82, 949-958.
61. Berger, S. I., Iyengar, R., Network analyses in systems pharmacology. Bioinformatics 2009, 25, 2466-2472.
62. Sillaber, C., Herrmann, H., Bennett, K., Rix, U. et al., Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily. Eur. J. Clin. Invest. 2009, 39, 1098-1109.
63. Hantschel, O., Rix, U., Schmidt, U., Burckstummer, T. et al., The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. USA 2007, 104, 13283-13288.
64. Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K. et al., TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008, 451, 725-729.
65. Hussain, S. F., Kong, L. Y., Jordan, J., Conrad, C. et al., A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007, 67, 9630-9636.
66. Deuse, T., Velotta, J. B., Hoyt, G., Govaert, J. A. et al., Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008, 85, 885-892.
67. Berger, S. I., Ma'ayan, A., Iyengar, R., Systems pharmacology of arrhythmias. Sci. Signal. 2010, 3, ra30.
68. Lage, K., Karlberg, E. O., Storling, Z. M., Olason, P. I. et al., A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat. Biotechnol. 2007, 25, 309-316.
69. Li, S., Zhang, N., Zhang, B., in: Chen, L., Zhang, X., Shen, B., Wu, L., Wang, Y. (Eds.), 4th International Conference on Computational Systems Biology, World Publishing Company, Suzhou, China 2010, pp. 51-58.
70. Gelb, B. D., Tartaglia, M., Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum. Mol. Genet. 2006, 15, R220-R226.
71. Goh, K. I., Cusick, M. E., Valle, D., Childs, B. et al., The human disease network. Proc. Natl. Acad. Sci. USA 2007, 104, 8685-8690.
72. Braun, P., Rietman, E., Vidal, M., Networking metabolites and diseases. Proc. Natl. Acad. Sci. USA 2008, 105, 9849-9850.
73. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L., Vidal, M., Drug-target network. Nat. Biotechnol. 2007, 25, 1119-1126.
74. Chen, C. Y., TCM DatabaseTaiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PLoS One 2011, 6, e15939.
75. Zhao, J., Jiang, P., Zhang, W., Molecular networks for the study of TCM pharmacology. Brief. Bioinform. 2010, 11, 417-430.
76. Li, S., Zhang, B., Zhang, N., Network target for screening synergistic drug combinations with application to traditional Chinese medicine. Biomed. Chromatogr. Syst. Biol. 2011, 5, S10.
77. Li, S., Zhang, B., Jiang, D., Wei, Y., Zhang, N., Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. Biomed. Chromatogr. Bioinformatics 2010, 11, S6.
78. Zeng, H., Dou, S., Zhao, J., Fan, S. et al., The inhibitory activities of the components of Huang-Lian-Jie-Du-Tang (HLJDT) on eicosanoid generation via lipoxygenase pathway. J. Ethnopharmacol. 2011, 135, 561-568.
79. Wang, L., Zhou, G. B., Liu, P., Song, J. H. et al., Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 2008, 105, 4826-4831.
80. Ung, C. Y., Li, H., Cao, Z. W., Li, Y. X., Chen, Y. Z., Are herbpairs of traditional Chinese medicine distinguishable from others? Pattern analysis and artificial intelligence classification study of traditionally defined herbal properties. J. Ethnopharmacol. 2007, 111, 371-377.
81. Kussmann, M., Role of proteomics in nutrigenomics and nutrigenetics. Expert Rev. Proteomics 2009, 6, 453-456.
82. Kussmann, M., Affolter, M., Proteomics at the center of nutrigenomics: comprehensive molecular understanding of dietary health effects. Nutrition 2009, 25, 1085-1093.
83. Shiyama, T., Furuya, M., Yamazaki, A., Terada, T., Tanaka, A., Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. Bioorg. Med. Chem. 2004, 12, 2831-2841.
84. Oda, Y., Owa, T., Sato, T., Boucher, B. et al., Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem. 2003, 75, 2159-2165.
85. Wang, G., Shang, L., Burgett, A. W., Harran, P. G., Wang, X., Diazonamide toxins reveal an unexpected function for ornithine delta-amino transferase in mitotic cell division. Proc. Natl. Acad. Sci. USA 2007, 104, 2068-2073.
86. Schirle, M., Heurtier, M. A., Kuster, B., Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol. Cell. Proteomics 2003, 2, 1297-1305.
87. Burkard, T. R., Planyavsky, M., Kaupe, I., Breitwieser, F. P. et al., Initial characterization of the human central proteome. Biomed. Chromatogr. Syst. Biol. 2011, 5, 17.
88. Trinkle-Mulcahy, L., Boulon, S., Lam, Y. W., Urcia, R. et al., Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes. J. Cell. Biol. 2008, 183, 223-239.
89. Winger, J. A., Hantschel, O., Superti-Furga, G., Kuriyan, J., The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). Biomed. Chromatogr. Struct. Biol. 2009, 9, 7.
90. Kandasamy, K., Mohan, S. S., Raju, R., Keerthikumar, S. et al., NetPath: a public resource of curated signal transduction pathways. Genome Biol. 2010, 11, R3.
91. Pico, A. R., Kelder, T., van Iersel, M. P., Hanspers, K. et al., WikiPathways: pathway editing for the people. PLoS Biol. 2008, 6, e184.
92. Xenarios, I., Salwinski, L., Duan, X. J., Higney, P. et al., DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res. 2002, 30, 303-305.
93. Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M. et al., The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011, 39, D561-D568.
94. Kuhn, M., Szklarczyk, D., Franceschini, A., Campillos, M. et al., STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res. 2010, 38, D552-D556.
95. Wheeler, D. L., Barrett, T., Benson, D. A., Bryant, S. H. et al., Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2008, 36, D13-D21.
96. Forbes, S. A., Tang, G., Bindal, N., Bamford, S. et al., COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010, 38, D652-D657.
97. Wishart, D. S., Knox, C., Guo, A. C., Cheng, D. et al., DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36, D901-D906.
98. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., Bork, P., A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 2010, 6, 343.
99. Frolkis, A., Knox, C., Lim, E., Jewison, T. et al., SMPDB: The small molecule pathway database. Nucleic Acids Res. 2010, 38, D480-D487.
100. Masciocchi, J., Frau, G., Fanton, M., Sturlese, M. et al., MMsINC: a large-scale chemoinformatics database. Nucleic Acids Res. 2009, 37, D284-D290.
101. de Matos, P., Alcantara, R., Dekker, A., Ennis, M. et al., Chemical entities of biological interest: an update. Nucleic Acids Res. 2010, 38, D249-D254.
102. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L., Ideker, T., Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011, 27, 431-432.
103. Kozhenkov, S., Dubinina, Y., Sedova, M., Gupta, A. et al., BiologicalNetworks 2.0 - an integrative view of genome biology data. Biomed. Chromatogr. Bioinformatics 2010, 11, 610.
104. Saeed, A. I., Sharov, V., White, J., Li, J. et al., TM4: A free, open-source system for microarray data management and analysis. Biotechniques 2003, 34, 374-378.
105. Grosdidier, A., Zoete, V., Michielin, O., SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 2011, 39, W270-W277.